Price movement over the last 24 hours
ADMA Biologics Inc vs e l f Beauty Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while e l f Beauty Inc trades at $74.3 (market cap $4.48B). The key difference: e l f Beauty Inc is far larger — about 2.1× ADMA Biologics Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ELF | |
|---|---|---|
Market Cap | $2.13B | $4.48B |
Sector | Health | Technology |
52-Week High | $20.38 | $146.67 |
52-Week Low | $7.60 | $49.57 |
Enterprise Value | $2.20B | $5.11B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ELF Beauty trades at $73.49, down 3.83% recently, but maintains a bullish technical outlook with strong support at $72. The company reported impressive earnings beats in recent quarters with Q4 2025 EPS of $1.24 beating expectations of $0.73. Revenue growth remains robust at $1.31 billion in 2025, though net margins are thin at 1.61%. Analyst sentiment is mixed with 46% buy ratings and a consensus price target of $72.82, slightly below current levels.
The stock faces valuation concerns with a high P/E of 173.68, but strong revenue growth and expansion into haircare and skincare categories provide upside potential. Key risks include tariff exposure and core brand momentum challenges. Institutional ownership trends and recent insider activity suggest cautious optimism as the company executes its diversification strategy.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →